Replimune Group Valuation Multiples

Replimune Group Overview

About Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Founded

2017

HQ

Employees

479

Website

replimune.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($314M)

EV

$389M

Valuation Multiples

Multiples.vc

Start free trial

Replimune Group Financials

Replimune Group reported last 12-month revenue of $2M and negative EBITDA of ($314M).

In the same LTM period, Replimune Group generated $360K in gross profit, ($314M) in EBITDA losses, and had net loss of ($302M).

Replimune Group P&L

In the most recent fiscal year, Replimune Group reported revenue of — and EBITDA of ($235M).

Replimune Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

Replimune Group Stock Performance

Replimune Group has current market cap of $581M, and enterprise value of $389M.

Replimune Group's stock price is $7.04.

Replimune Group Valuation Multiples

Replimune Group trades at 241.3x EV/Revenue multiple, and (1.2x) EV/EBITDA.

Replimune Group Financial Valuation Multiples

As of March 18, 2026, Replimune Group has market cap of $581M and EV of $389M.

Equity research analysts estimate Replimune Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Replimune Group has a P/E ratio of (1.9x).

Replimune Group Margins & Growth Rates

Replimune Group's revenue in the last 12 month grew by 3452%.

Replimune Group's revenue per employee in the last FY averaged $0.0M.

Replimune Group's rule of 40 is (16038%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Replimune Group's rule of X is (10860%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Replimune Group Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Replimune Group M&A Activity

Replimune Group acquired XXX companies to date.

Last acquisition by Replimune Group was on XXXXXXXX, XXXXX. Replimune Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Replimune Group Investment Activity

Replimune Group invested in XXX companies to date.

Replimune Group made its latest investment on XXXXXXXX, XXXXX. Replimune Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).